American Academy of Optometry (AAOpt) Annual Meeting 2020 Virtual Congress ProQR participation in the American Academy of Optometry Annual Meeting 2020 October 07, 2020
Oligonucleotide and Precision Therapeutics (OPT) Congress Congress ProQR presentation and panel session at the Oligonucleotide and Precision Therapeutics (OPT) Congress March 14, 2023
Structure-based computational approach for optimizing oligonucleotides for A-to-I editing Poster Applicability of a structure-based modelling approach as a tool for in silico screening of oligonucleotides for targeted RNA editing presented at Oligonucleotide Therapeutics Society (OTS) 2018 by Julien Boudet September 30, 2018
ProQR Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares Press release LEIDEN, The Netherlands, Sept. 23, 2014 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 23, 2014
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, the Netherlands and CAMBRIDGE, Mass., Oct. 18, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. October 18, 2019
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., Sept. 11, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. September 11, 2018
ProQR Announces Closing of Underwritten Public Offering of Ordinary Shares with Full Exercise of Underwriters’ Option to Purchase Additional Shares Press release LEIDEN, Netherlands and CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. April 05, 2021
Privacy Page This privacy statement informs our website visitors on what, for what purposes and how we process personal data.
ProQR founding story Page When our CEO, Daniel A. de Boer, knew his newborn son had an incurable rare disease, he founded ProQR to help people like his son. Learn more.